Sweden and Denmark – this is how they choose their strategies

Scandinavia’s two major powers in pharmaceutical research have developed strategies for growth in life science, and both countries aim to become world leaders.

Academia - a strong player on the lab market

While the industry was short of money during the financial crisis, government incentives were in full swing in Sweden during 2009. - Our sales to academia incre...

A world-class research village

Eight years ago, Medicon Village was set up in Lund. Since then, this hub for research, innovation and business has developed enormously, and today the life sci...

With their hands on the legal levers

It is wonderful news for the Scandinavian scientific community. At the end of May it stood clear that Lund will host to the European Spallation Source.

Delivering drugs with small devices

There are many challenges to overcome when delivering a drug orally. Getting the drug to survive the low pH of the ventricle and being released at the correct s...

Swedish Healthtech Company 1928 Pushing Forward

The full service analytics platform is expanding the business.

Pfizer lays a chunky bid on Wyeth

The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at app...

EU grants project on toxicity of nanomaterials

A multinational research project has have been awarded EUR 3 358 500 from the European Commission to study the hazardous effects of engineered nanomaterials on ...

No demand for new Covid vaccine – “It will probably be discarded”

So far, just under 6 000 doses of the Covid vaccine from Novavax have been used in Sweden, leaving over 1.4 million doses in stock. “They will probably be disca...

Samuel Lagercrantz: Collaboration and joint efforts are the key to success

Although many questions about Covid-19 remain unanswered, the development of drugs and vaccines has been incredibly rapid, writes Samuel Lagercrantz, Life Scien...

Engage with your CMO early

Gordon Hutton is Materials Science Lead at Thermo Fisher Scientific’s, formerly GSK, small molecule API site in Cork, Ireland.

Combining two drug delivery strategies to improve bioavailability

Danish researchers hope to increase the bioavailability of low solubility drugs.

IRW Consulting is seeking Clinical Research Associates (CRAs) on positions located in Stockholm

Pharma Outsourcing igång på Stockholm Waterfront

180 cancerforskare samlas digitalt i Lund

Medicon Village och Lunds universitet ordnar ett digitalt möte på Världscancerdagen på torsdag.

From spin-off to phase II

”The people there will basically become your new colleagues” – Carina Schmidt, former CEO of Athera, about working with different contractors.

Digitalisering av in vivo-data ska underlätta för forskare

Problem med stora datamängder väckte en idé hos forskaren Sara Mangsbo och hennes kollegor på Vivologica, som utvecklade en mjukvaruplattform som underlättar fö...

It´s time to establish relations

Communication with the patient is the key to future healthcare, writes Hanna Brodda, editor in chief of Life Science Sweden.

Brexit creeping closer – or?

In this column, lawyer Pernilla Norman, tries to sort out the different Brexit options.

The perfect formula for decision-making

No one has the luxury not to take a decision, writes Helena Strigård at Swedenbio.

Anna Törner: Success requires bold decisions!

“Doing things right is fine, but doing the right things as soon as possible is even better”, writes Anna Törner in a column.

Before you choose a CRO

– We are a small company and it is very important for us to maintain our core competence within development of novel nanomaterials, Tove Sivik Sonne, Head of De...

Giulia Gaudenzi: ”Key lessons from global health research”

The world will still face major challenges in the post Covid-19 pandemic, writes Giulia Gaudenzi at the KTH Division of Nanobiotechnology at Scilifelab, in a column.

Myndigheterna till företagen: samarbeta under pandemin

Det internationella samarbetsorganet för läkemedelsmyndigheter slår ett slag för stora välgenomförda studier och samarbete mellan olika aktörer.